Positions

Overview

  • I am dual-trained in both Medical Hematology/Oncology and Clinical Pharmacology and Pharmacogenomics at the University of Chicago. My specialty training allowed me to develop expertise in clinical trial design, pharmacokinetics (PK)/pharmacodynamics (PD) analysis, drug development, and patient care. In September 2015, I joined the faculty at the University of Alabama at Birmingham as an Assistant Professor of Medicine. My focus remains in highly aggressive women’s malignancies (i.e. triple-negative and HER2+ breast cancer as well as high-grade serous ovarian cancer) and early-phase clinical trial design. In this role, I serve as a clinician-scientist helping laboratory-based scientist translate laboratory findings to the clinical setting by designing trials.
  • Research Overview

  • Breast Cancer Ovarian Cancer Developmental Therapeutics Translational Research
  • Investigator On

  • Private Grant  awarded by Pfizer Pharmaceuticals 2017 - 2025
  • UAB17127:A phase Ib trial of fulvestrant, palbociclib (CDK4/6 inhibitor) and erdafitinib (JNJ- 42756493, pan-FGFR tyrosine kinase inhibitor) in ER+/HER2–/FGFR-amplified metastatic breast cancer (MBC)  awarded by VANDERBILT UNIVERSITY 2018 - 2023
  • Private Grant  awarded by ELI LILLY AND COMPANY 2018 - 2023
  • Private Grant  awarded by Genentech 2018 - 2023
  • Private Grant  awarded by ZYMEWORKS BIOPHARMACEUTICALS 2018 - 2023
  • XUAB 17109-TBCRC 038: Diversity in the Tumor Genome and Microenvironment as Drivers of DCIS Progression  awarded by Johns Hopkins University 2018 - 2023
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2016 - 2022
  • TBCRC 035 UAB 15114: Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II Study with Pharmacodynamics Markers (TBCRC 35)  awarded by Johns Hopkins University 2016 - 2021
  • Private Grant  awarded by SYNDAX PHARMACEUTICALS 2016 - 2021
  • Private Grant  awarded by TESARO, INC. 2016 - 2021
  • Private Grant  awarded by ELI LILLY AND COMPANY 2016 - 2021
  • Private Grant  awarded by INNOCRIN PHARMACEUTICALS, INC. 2016 - 2021
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2017 - 2021
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2016 - 2021
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2016 - 2021
  • Private Grant  awarded by EMD SERONO 2016 - 2021
  • Private Grant  awarded by INCYTE CORPORATION 2016 - 2021
  • UAB 1643- A Randomized Phase II Trial of Fulvestrant With or Without Ribociclib After Progression on Aromatase Inhibition Plus Cyclin-Dependent Kinase 4/6 Inhibition in Patients with Unresectable or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer  awarded by Columbia University 2016 - 2020
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2015 - 2020
  • TBCRC 038: Diversity in the Tumor Genome and Microenvironment as Drivers of DCIS Progession  awarded by Duke University 2018 - 2020
  • Private Grant  awarded by INCYTE CORPORATION 2015 - 2020
  • Southwest Oncology Group Purchase Service Agreement  awarded by Oregon Health & Science University 2015 - 2020
  • TBCRC030 - A Randomized Phase II Study of Preoperative Cisplatin versus Paclitaxel in Patients with Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker  awarded by Johns Hopkins University 2014 - 2019
  • Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect  awarded by University of Wisconsin-Madison 2016 - 2019
  • XUAB 1769: Phase lb 9cUAB30 In Early Stage Breast Cancer to Evaluate Biologic Effect (Cost Reimbursable)  awarded by University of Wisconsin-Madison 2016 - 2019
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2014 - 2019
  • TBCRC 026/UAB 1367: A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) with Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients with Primary Operable HER2-Positive Breast Cancer (ML28190)  awarded by Johns Hopkins University 2014 - 2019
  • Utilizing Multiomic Advanced Diagnostics to Identify Palbociclib Response Predictors and a Post-treatment Multiomic Signature for Patients with ER+/HER2- Metastatic Breast Cancer  awarded by THE SIDE-OUT FOUNDATION 2017 - 2019
  • UAB 1174: Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2  awarded by QUANTUM LEAP HEALTH CARE 2012 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2015 - 2019
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2019
  • TBCRC 036 (UAB 1366): Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab + Pertuzumab, or Combination Trastuzumab + Lapatinib  awarded by Lineberger Comprehensive Care Center 2014 - 2019
  • TBCRC 033 UAB 1568: A Randomized Phase II study of Adjuvant Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination with Trastuzumab for Stage 1 HER2-Positive Breast Cancer (ATEMPT Trial)  awarded by Dana-Farber Cancer Institute 2015 - 2018
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC 2017 - 2018
  • Education And Training

  • Bachelor of Science or Mathematics in Biomedical Sciences, Auburn University
  • Doctor of Medicine, University of South Alabama
  • Full Name

  • Erica Stringer-Reasor
  • Blazerid

  • strinem